COVID-19 Further Overwhelms Chest Pain Triage Inefficiencies

Partner News | Published: Wednesday, April 1, 2020 6:00 am

The traditional pathway for the evaluation of potential Acute Coronary Syndrome is a clinically and economically inefficient process. Patients entering the hospital for chest pain may be kept for an 8-23-hour stay1, even though close to 80% of these patients have non-cardiac related chest pain2. This extended length of stay is often the result of a large percent of indeterminate test results, strained hospital resources and the time required to assure the absence of an evolving myocardial infarction. 

COVID-19 has further overwhelmed this process; the points below illustrate the recent additional strain on the hospital system.

  1. COVID-19 is causing a large rise in non-cardiac elevations of biomarkers, sometimes just due to general multiorgan fulminant inflammation, severely complicating the traditional methods to diagnose myocardial infarction3
  2. The lengthy chest pain triage process risks exposing non-infected patients and staff to COVID-19 patients, causing additional consumption of personal protective equipment for patients who are not presenting with viral symptoms. 
  3. Technicians and physicians responsible for the usual follow-ups to these positive tests (i.e. echo, nuclear stress test, etc.) have even less time to tend to these patients.  
  4. Two-thirds of U.S. hospitals are already occupied4. Keeping patients that could be discharged, will soon cost a life.

Prior to the COVID-19 crisis, Genetesis was working to save healthcare facilities, time, money and resources with a 90-second noninvasive CardioFlux scan. Now with the COVID-19 pandemic at top of mind, CardioFlux has emerged as a potential solution for exhausted and over-extended healthcare providers, seeking to quickly differentiate patients with coronary artery disease from those who would not benefit from further invasive tests. 

Dr. Randall Wolf, a leading innovator in minimally invasive treatment of atrial fibrillation and the pioneer of both DaVinci cardiac surgery and the Wolf Minimaze procedure, said, “CardioFlux is in a unique position to rule out myocardial ischemia in an emergency room scenario, since the rapid test requires no contact with the patient, no IV, no injection and can be performed with social distancing. This is what we need now.”

Genetesis is a medical technology company focused on redefining the way myocardial ischemia and coronary arterial occlusive disease are detected. The CardioFlux Magnetocardiograph, is an FDA cleared, non-invasive, functional biomagnetic imaging system that measures the natural magnetic fields produced by the electrical activity in the heart.

Furthermore, all CardioFlux scans are performed at rest, with absolutely no patient exposure to radiation or pharmaceuticals.

CardioFlux leverages Magnetocardiography (MCG), a 40+ year old science that has previously been constrained by technical feasibility and heavy recurring investments. CardioFlux has overcome these barriers of the past, and its technical advancements are poised to be easily integrated into clinical workflows.

To learn how CardioFlux could be leveraged at your facility, please contact John Hart, VP of Global Commercial Operations,


1 -

2 -

3 -

4 -




This site uses cookies to improve your experience.

By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.